Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.36 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 8/20 | 0.35 |
| ▸ | RAB9A | P51151 | 8/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.35 |
| ▸ | MAPT | P10636 | 4/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | CASR | P41180 | 1/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4474004 | 0.86 | RAB9A (0.41) | MAPK1MEN1KMT2ACRBNDDB1 | |
| SCHEMBL4473864 | 0.75 | HSD17B10 (0.38) | MAPK1MEN1KMT2ATSHRHPGD | |
| SCHEMBL4468239 | 0.75 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL4473362 | 0.73 | — | — | |
| SCHEMBL4484839 | 0.73 | MEN1 (0.34) | MEN1KMT2AMAPTHPGDHSD17B10 | |
| SCHEMBL4463115 | 0.72 | CYP11B2 (0.34) | — | |
| SCHEMBL4464111 | 0.71 | SSTR5 (0.35) | — | |
| SCHEMBL4472455 | 0.71 | SPR (0.34) | MEN1KMT2ASMN1; SMN2POLBLMNA | |
| SCHEMBL4481197 | 0.71 | GRM5 (0.35) | — | |
| SCHEMBL4472622 | 0.69 | SSTR5 (0.39) | MEN1KMT2AMAPTHPGDPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060128790-A1 | Spiro derivatives as lipoxygenase inhibitors | GALILEO PHARMACEUTICALS, INC. | 2006-06-15 | — | — | US | claimed |
| US-7576094-B2 | Spiro derivatives as lipoxygenase inhibitors | ELI LILLY AND COMPANY (US) | 2009-08-18 | — | — | US | disclosed |
| US-7576094-B2 | Spiro derivatives as lipoxygenase inhibitors | ELI LILLY AND COMPANY (US) | 2009-08-18 | — | — | US | disclosed |
| US-7576094-B2 | Spiro derivatives as lipoxygenase inhibitors | ELI LILLY AND COMPANY (US) | 2009-08-18 | — | — | US | disclosed |
| EP-1836183-A2 | SPIRO DERIVATIVES AS LIPOXYGENASE INHIBITORS | Galileo Pharmaceuticals, Inc. (US) | 2007-09-26 | — | — | EP | disclosed |
| WO-2006065686-A2 | SPIRO DERIVATIVES AS LIPOXYGENASE INHIBITORS | GALILEO PHARMACEUTICALS, INC. (US) | 2006-06-22 | — | — | WO | disclosed |
| US-20060128790-A1 | Spiro derivatives as lipoxygenase inhibitors | GALILEO PHARMACEUTICALS, INC. | 2006-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128790-A1 | Spiro derivatives as lipoxygenase inhibitors | ALOX15B, ALOX5, ALOX15 | MAPK1 3506/4885MEN1 4420/4885KMT2A 3967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.